Aripiprazole and risperidone in treatment of methamphetamine associated psychosis in China: A pilot randomized study

Vivitrol®) for reducing cocaineuse inparticipantswhometDSMIV criteria for cocaine dependence and past or current opioid dependence or abuse. Methods: This multi-centered, double-blind, placebocontrolled study provided XR-NTX to 302 participants before random assignment to 1 of 3 daily sublingual BUP conditions: 4mg BUP (BUP4, n=100), 16mg BUP (BUP16, n=100), and 0mg BUP (PLB, n=102). Participants received pharmacotherapy for 8 weeks, with thrice-weekly clinic visits for observed dosing, provision of takehome medication, urine drug screening (UDS), and assessments. Cognitive Behavioral Therapy was provided weekly. Follow-up assessments occurred at 1 and 3 months post-intervention. Results: Planned primary analyses of self-reported cocaine use corrected by UDS found no difference in cocaine use during the last 4 weeks of medication (weeks 4–8) between placebo and each BUP group (BUP4 vs PLB, p=0.143, BUP16 vs PLB, p=0.165). Secondary longitudinal analysis of UDS found a significant difference between BUP16 and PLB (p=0.030), but no difference betweenBUP4 and PLB (p=0.529). No differences across groupswere found for adherence, retention, or adverse events. Conclusions: Although the primary outcome analysis did not find a treatment effect, other analyses suggest that treatment with buprenorphine/naloxone, used in combination with naltrexone, may be beneficial in reducing cocaine use for some individuals. Future studies to evaluate this medication combination pharmacotherapy for cocaine use disorder appear warranted. Financial support: DA13045.